Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Bijan-Michael Ghadimi
Introduction
Bijan-Michael Ghadimi is a notable inventor based in Bethesda, MD, who has made significant contributions to the field of cancer research. His work primarily focuses on the detection and treatment response of rectal adenocarcinomas, which is crucial for improving patient outcomes.
Latest Patents
Ghadimi holds a patent for a composition that detects the response of rectal adenocarcinomas to radiochemotherapy. This innovative patent involves a cDNA array consisting of 9984 genes used for expression profiling in rectal adenocarcinoma. The expression data obtained from this array were correlated to the responsiveness of tumors to chemotherapy followed by radiotherapy. Notably, a set of 54 genes was identified as differentially expressed in responders versus non-responders. These genes may serve as prognostic markers to determine whether a rectal adenocarcinoma is responsive to radiochemotherapy.
Career Highlights
Ghadimi is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His role at this prestigious institution allows him to contribute to groundbreaking research that has the potential to change the landscape of cancer treatment.
Collaborations
Throughout his career, Ghadimi has collaborated with esteemed colleagues, including Thomas Ried and Michael J Difilippantonio. These collaborations have further enhanced the impact of his research and innovations in the field.
Conclusion
Bijan-Michael Ghadimi's work exemplifies the importance of innovation in cancer research. His contributions, particularly in the area of rectal adenocarcinoma treatment response, highlight the potential for scientific advancements to improve patient care and outcomes.